Loading clinical trials...
Loading clinical trials...
A Phase 3, Open-label, Non-controlled, Multi-dose, Extension Study to Evaluate the Long-term Safety and Tolerability of IGSC, 20% in Japanese Subjects With Primary Immunodeficiency Disease (PID)
Conditions
Interventions
IGSC 20% infusion
Locations
8
Japan
Nagoya University Hospital
Nagoya, Aichi-ken, Japan
Kurume University Hospital
Kurume, Fukuoka, Japan
Kanazawa University Hospital
Kanazawa, Ishikawa-ken, Japan
National defense medical college Hospital
Tokorozawa, Saitama, Japan
Kyushu University Hospital
Fukuoka, Japan
Gifu University Hospital
Gifu, Japan
Start Date
April 27, 2021
Primary Completion Date
April 25, 2024
Completion Date
April 25, 2024
Last Updated
January 20, 2025
NCT07346859
NCT04944979
NCT05236764
NCT05755035
NCT05513586
NCT06955793
Lead Sponsor
Takeda
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions